Hims & Hers Health has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, ...

After a tumultuous year, a popular virtual care platform is trying its hand in a competitive blood testing market.

Shares of Hims & Hers are trading marginally lower Monday morning, as competitive news overshadows bullish announcements from ...

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 4.9% in the afternoon session after news of ...

Novo Nordisk cuts obesity drug prices to compete with Eli Lilly, offering new patient deals and nationwide access.

Novo Nordisk A/S is undercutting archrival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness to compete on price as it tries to claw back a larger share of the U.S.

Global populations are aging, a reality that is leading to increased demand for healthcare services, chronic disease ...

The Denmark-based company on Monday said it will offer the first two monthly doses of Wegovy and Ozempic for $199 a month to those who pay in cash between now and March 31 of next year. After those ...

Investors delivered a harsh verdict on Hims & Hers Health's latest financial results, driving shares down sharply despite what appeared to be strong oper ...

Shares of Mangoceuticals surged 28% ‌to $2.25 in premarket trading. U.S. regulations allow compounding pharmacies to copy ...

How Ozempic Is Changing Thanksgiving According to the independent research and polling source KFF, one in eight Americans reported taking a GLP-1 receptor agonist ...

This expansion into diagnostics and tailored care represents a logical strategic extension of the company's telehealth model. Yet, the market's focus remained fixed on the worrying traffic and ...